The PMGK group was created in 2013 with the appointment of L. Elens as a professor in pharmacogenomics and pharmacokinetics. The principal focus of this group is the development and the harmonization of personalized medicine. It mainly aims at characterizing the pharmacokinetic (PK) behavior of drugs in humans using quantitative approaches. The research activities cover multiple fields of expertise such as PK, Pharmacodynamics (PD), Population PK (PPK), Pharmacogenomics (Pgx) and PK-PD relationships, all being essential for the understanding of the fate of xenobiotics administered in humans. More specifically, the PK as well as the Pgx expertise covers in silico, in vitro and in vivo approaches of drug metabolism, all indispensable and complementary to elucidate the determinants of therapeutic responses.